MedTrace Logo

Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis

NCT04090294 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2019-10-03

No results posted yet for this study

Summary

Aim of the work

Assessment of early outcome of using Roflumilast in patients with bronchiectasis regarding:

* Severity of symptoms
* Frequency of exacerbations
* Change in pulmonary function
* Systemic inflammation

Conditions

Interventions

DRUG

Roflumilast

Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test. patients will receive Roflumilast 500 Mcg. Tablet once daily for three months

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ahmad Shaddad, Lecturer · Assuit University - Assuit - Egypt

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-09-30
Completion
2020-11-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04090294 on ClinicalTrials.gov